PT - JOURNAL ARTICLE AU - Puzi Jiang AU - Sicheng Wu AU - Xing-ming Zhao AU - Wei-Hua Chen TI - Metagenomic analysis of common intestinal diseases reveals relationships among microbial signatures and powers multi-disease diagnostic models AID - 10.1101/19013136 DP - 2019 Jan 01 TA - medRxiv PG - 19013136 4099 - http://medrxiv.org/content/early/2019/11/29/19013136.short 4100 - http://medrxiv.org/content/early/2019/11/29/19013136.full AB - Intestinal diseases can share clinical symptoms and gut microbiome alterations, necessitating cross-disease comparisons and the use of multi-disease models. Here, we performed meta-analyses on fecal metagenomes of Crohn’s disease (CD), ulcerative colitis (UC) and colorectal cancer (CRC), and identified 65 marker species and 74 marker pathways that were significantly altered in >=2 studies of the same disease. We grouped marker species by their co-occurrences into disease-specific and mixed clusters according to whether all the cluster members belong to the same disease, and revealed their distinct phylogenetic relationships: species in disease-specific clusters are phylogenetically related, while those in mixed clusters are more distant; strikingly, UC- and CRC-specific species are phylogenetically closer than to CD-specific ones, likely because UC-patients have higher risk of CRC. Consistent to their phylogenetic relationships, marker species had similar within-cluster and different between-cluster metabolic preferences. In CD and CRC, most marker species correlated with an indicator of leaky gut, suggesting a link between gut dysbiosis and human derived contents. In fact, our results suggested that due to physio-metabolic alterations, the diseased gut may represent a stressed environment and pose stronger selection to gut microbes; consequently, marker species in diseases showed more coordinated changes than the controls. With the marker species and pathways, we constructed three high-performance (including multi-disease) models with AUROC of 0.88 and true positive rates up to 89%, and explained their putative clinical applications. Together, our results improved our understanding on the relationships among common intestinal diseases, and strongly support the feasibility of metagenome-based multi-disease diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly supported by National Key Research and Development Program of China 2018YFC0910502 (to W.H.C.), National Natural Science Foundation of China (61932008, 61772368, 61572363), National Key R&D Program of China (2018YFC0910500), Natural Science Foundation of Shanghai (17ZR1445600), Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJLab.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCorrespondence and requests for materials should be addressed to W.H.C. and X.M.Z..